RESUMEN
First-line diagnostic investigations for endometriosis are physical examination and pelvic ultrasound. The second-line investigations are: targeted pelvic examination performed by an expert clinician, transvaginal ultrasound performed by an expert physician sonographer (radiologist or gynaecologist), and pelvic MRI. Management of endometriosis is recommended when the disease has a functional impact. Recommended first-line hormonal therapies for the management of endometriosis-related pain are combined hormonal contraceptives (CHCs) or the 52mg levonorgestrel-releasing intrauterine system (IUS). There is no evidence base on which to recommend systematic preoperative hormonal therapy solely to prevent surgical complications or facilitate surgery. After surgery for endometriosis, a CHC or 52mg levonorgestrel-releasing IUS is recommended as first-line treatment when pregnancy is not desired. In the event of failure of the initial treatment, recurrence, or multiorgan involvement, a multidisciplinary team meeting is recommended, involving physicians, surgeons and other professionals. A laparoscopic approach is recommended for surgical treatment of endometriosis. HRT can be offered to postmenopausal women who have undergone surgical treatment for endometriosis. Antigonadotrophic hormonal therapy is not recommended for patients with endometriosis and infertility to increase the chances of spontaneous pregnancy, including postoperatively. Fertility preservation options must be discussed with patients undergoing surgery for ovarian endometriomas.
Asunto(s)
Endometriosis/tratamiento farmacológico , Ginecología , Obstetricia , Guías de Práctica Clínica como Asunto , Sociedades Médicas , Endometriosis/diagnóstico , Endometriosis/cirugía , Femenino , Francia , Ginecología/normas , Humanos , Obstetricia/normas , Guías de Práctica Clínica como Asunto/normas , Sociedades Médicas/normasRESUMEN
First-line investigations to diagnose endometriosis are clinical examination and pelvic ultrasound. Second-line investigations include pelvic examination performed by a referent clinician, transvaginal ultrasound performed by a referent echographist, and pelvic MRI. It is recommended to treat endometriosis when it is symptomatic. First-line hormonal treatments recommended for the management of painful endometriosis are combined with hormonal contraceptives or levonorgestrel 52mg IUD. There is no evidence to recommend systematic preoperative hormonal therapy for the unique purpose of preventing the risk of surgical complications or facilitating surgery. After endometriosis surgery, combined hormonal contraceptives or levonorgestrel SIU 52mg are recommended as first-line therapy in the absence of desire of pregnancy. In case of initial treatment failure, recurrence, or multiple organ involvement by endometriosis, medico-surgical and multidisciplinary discussion is recommended. The laparoscopic approach is recommended for the surgical treatment of endometriosis. HRT may be offered in postmenopausal women operated for endometriosis. In case of infertility related to endometriosis, it is not recommended to prescribe anti-gonadotropic hormone therapy to increase the rate of spontaneous pregnancy, including postoperatively. The possibilities of fertility preservation should be discussed with the patient in case of surgery for ovarian endometrioma.
Asunto(s)
Endometriosis/diagnóstico , Endometriosis/terapia , Terapias Complementarias , Anticonceptivos Hormonales Orales , Diagnóstico por Imagen , Femenino , Examen Ginecologíco , Humanos , Infertilidad Femenina/etiología , Infertilidad Femenina/terapia , Educación del Paciente como Asunto , Dolor Pélvico/tratamiento farmacológico , Dolor Pélvico/etiologíaRESUMEN
A patient with pancytopenia and hypercellular bone marrow but without evidence of hemolysis had a positive direct antiglobulin test due to a red blood cell autoantibody. Although the patient was K-negative, eluates made from his erythrocytes contained what seemed to be anti-K antibody. The latter could be adsorbed onto and eluted from both K-positive and K-negative cells. We concluded that this patient is another example of autoanti-K antibody mimicking an alloanti-K antibody.